Integra Lifesciences Analyst Price Targets

PRO

Pourquoi cela bouge-t-il ?:Integra Lifesciences shares are trading lower after the company reported wo...

Résultats: Les résultats Q3 2026 ont été publiés le mer. oct. 21st, avant l'ouverture du marché

Conférence téléphonique: La conférence téléphonique la plus récente a commencé à 8:30 AM, il y a 1 jour

Cliquez pour voir la webdiffusion

Integra Lifesciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Integra Lifesciences (IART).

Price Target Range — 12 Quarters

Analyst Consensus — 12 Analysts

2S.Buy

1Buy

6Hold

3Sell

Consensus RatingMarket Outperform# Analysts12Avg. Consensus PT$21Upside to Avg. PT+80.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 14, 2026	Truist Securities	Ravi Misra	PT Cut	Hold	$19→$15
Oct 5, 2026	Citigroup	Joanne Wuensch	PT Cut	Neutral	$19→$15
Oct 5, 2026	BMO Capital	Vik Chopra	PT Cut	Market Perform	$18→$15
Jul 30, 2026	Wells Fargo	Larry Biegelsen	PT Raise	Equal-Weight	$15→$18
Jul 28, 2026	UBS	Patrick Wood	Initiate	Neutral	$19
Jul 16, 2026	Truist Securities	Ravi Misra	PT Raise	Hold	$14→$19
Jul 9, 2026	BMO Capital	Vik Chopra	Initiate	Market Perform	$19
Jul 8, 2026	Citigroup	Joanne Wuensch	PT Raise	Neutral	$16→$19
May 28, 2026	Citigroup	Joanne Wuensch	Upgrade	Sell→Neutral	$11→$16
May 6, 2026	Citigroup	Joanne Wuensch	PT Raise	Sell	$9→$11
May 6, 2026	Wells Fargo	Larry Biegelsen	PT Raise	Equal-Weight	$12→$15
Apr 15, 2026	Truist Securities	Ravi Misra	PT Cut	Hold	$13→$12
Apr 15, 2026	Argus Research	David Toung	Downgrade	Buy→Hold	—
Mar 11, 2026	Citigroup	Joanne Wuensch	PT Cut	Sell	$11→$9
Feb 27, 2026	Wells Fargo	Vik Chopra	PT Cut	Equal-Weight	$13→$12
Nov 3, 2025	Truist Securities	Ravi Misra	PT Cut	Hold	$15→$13
Oct 31, 2025	Citigroup	Joanne Wuensch	PT Cut	Sell	$12→$11
Oct 31, 2025	JP Morgan	Robbie Marcus	PT Raise	Underweight	$12→$13
Oct 15, 2025	Truist Securities	Richard Newitter	PT Raise	Hold	$13→$15
Oct 7, 2025	Citigroup	Joanne Wuensch	PT Raise	Sell	$10→$12

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Truist Securities Maintains Hold on Integra Lifesciences, Lowers Price Target to $15

Truist Securities analyst Ravi Misra maintains Integra Lifesciences (NASDAQ:IART) with a Hold and lowers the price target from $19 to $15.

Benzinga Newsdesk

PRO
BMO Capital Maintains Market Perform on Integra Lifesciences, Lowers Price Target to $15

BMO Capital analyst Vik Chopra maintains Integra Lifesciences (NASDAQ:IART) with a Market Perform and lowers the price target from $18 to $15.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on Integra Lifesciences, Raises Price Target to $18

Wells Fargo analyst Larry Biegelsen maintains Integra Lifesciences (NASDAQ:IART) with a Equal-Weight and raises the price target from $15 to $18.

Benzinga Newsdesk

PRO
UBS Initiates Coverage On Integra Lifesciences with Neutral Rating, Announces Price Target of $19

UBS analyst Patrick Wood initiates coverage on Integra Lifesciences (NASDAQ:IART) with a Neutral rating and announces Price Target of $19.

Benzinga Newsdesk

PRO
Truist Securities Maintains Hold on Integra Lifesciences, Raises Price Target to $19

Truist Securities analyst Ravi Misra maintains Integra Lifesciences (NASDAQ:IART) with a Hold and raises the price target from $14 to $19.

Benzinga Newsdesk

PRO
BMO Capital Initiates Coverage On Integra Lifesciences with Market Perform Rating, Announces Price Target of $19

BMO Capital analyst Vik Chopra initiates coverage on Integra Lifesciences (NASDAQ:IART) with a Market Perform rating and announces Price Target of $19.

Benzinga Newsdesk

Integra Lifesciences Holdings Corp

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Integra Lifesciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Truist Securities Maintains Hold on Integra Lifesciences, Lowers Price Target to $15

PRO
BMO Capital Maintains Market Perform on Integra Lifesciences, Lowers Price Target to $15

PRO
Wells Fargo Maintains Equal-Weight on Integra Lifesciences, Raises Price Target to $18

PRO
UBS Initiates Coverage On Integra Lifesciences with Neutral Rating, Announces Price Target of $19

PRO
Truist Securities Maintains Hold on Integra Lifesciences, Raises Price Target to $19

PRO
BMO Capital Initiates Coverage On Integra Lifesciences with Market Perform Rating, Announces Price Target of $19

People Also Watch

People Also Watch

Integra Lifesciences Holdings Corp

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Integra Lifesciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROTruist Securities Maintains Hold on Integra Lifesciences, Lowers Price Target to $15

PROBMO Capital Maintains Market Perform on Integra Lifesciences, Lowers Price Target to $15

PROWells Fargo Maintains Equal-Weight on Integra Lifesciences, Raises Price Target to $18

PROUBS Initiates Coverage On Integra Lifesciences with Neutral Rating, Announces Price Target of $19

PROTruist Securities Maintains Hold on Integra Lifesciences, Raises Price Target to $19

PROBMO Capital Initiates Coverage On Integra Lifesciences with Market Perform Rating, Announces Price Target of $19

People Also Watch

People Also Watch

PRO
Truist Securities Maintains Hold on Integra Lifesciences, Lowers Price Target to $15

PRO
BMO Capital Maintains Market Perform on Integra Lifesciences, Lowers Price Target to $15

PRO
Wells Fargo Maintains Equal-Weight on Integra Lifesciences, Raises Price Target to $18

PRO
UBS Initiates Coverage On Integra Lifesciences with Neutral Rating, Announces Price Target of $19

PRO
Truist Securities Maintains Hold on Integra Lifesciences, Raises Price Target to $19

PRO
BMO Capital Initiates Coverage On Integra Lifesciences with Market Perform Rating, Announces Price Target of $19